World Library  
Flag as Inappropriate
Email this Article
 

Marc Lacroix (biochemist)

Marc Guy Albert Marie Lacroix [pronunciation: "mɑːk lakʁwa"] is a biochemist (educated at University of Liège) and a researcher (born 28 April 1963 in Verviers, Wallonia, Belgium) who specializes in breast cancer biology, metastasis and therapy.[1][2][3][4][5][6][7][8][9]

He works at Institut Jules Bordet (Brussels, Belgium). He lives in Baelen

Contents

Earlier work

Breast cancer cells (BCC) frequently metastasize to the skeleton, where they lead to tumor-induced osteolysis and subsequent morbidity. Marc Lacroix has investigated the interrelationships between BCC and bone cells (osteoblasts, the bone-building cells, and osteoclasts, the bone-degrading cells). With colleagues, he discovered that BCC produce soluble factors increasing osteoclast activity, notably interleukin-11, the production of which is reduced by the cyclooxygenase inhibitor aspirin.[10][11][12] BCC also reduce the proliferation of osteoblasts and their production of collagen, the main protein component of bone.[13][14][15] Marc Lacroix also examined the response BCC to the anti-osteolytic agent calcitonin[16][17]

In close collaboration with Prof. Guy Leclercq (Laboratoire Jean-Claude Heuson de Cancérologie Mammaire, Institut Jules Bordet, Belgium), Marc Lacroix has studied various aspects of estrogen receptor biology, ligand-binding and transcriptional activity, and life-cycle.[18][19][20][21][22][23][24][25][26]

Recent work

The amount of data on breast cancer available for the scientific and medical community is growing rapidly. According to biology, pathology and genetics of in situ, invasive and metastatic breast cancers. These papers were covering a time period of about 25 years. Lacroix et al. concluded that despite undergoing increasing genetic alteration, most individual breast cancers rather surprisingly maintain their phenotype when they evolve from in situ to the metastatic state.[27] This conclusion was in opposition to a progression model widely accepted at that time, which was suggesting that carcinoma in situ could evolve into invasive carcinoma and subsequently produce metastases through an accumulation of molecular abnormalities possibly allowing extensive phenotype changes and subsequent gain of aggressiveness.

Bibliography: articles in scientific and medical journals (excerpt)

  1. ^ Siwek, B; Larsimont D; Lacroix M; Body JJ (1998). "Establishment and characterization of three new breast-cancer cell lines". International Journal of Cancer 76 (5): 677–683.  
  2. ^ Lacroix, M; Zammatteo N; Remacle J; Leclercq G. (2002). "A low-density DNA  
  3. ^ Lacroix, M; Leclercq G. (2004). "Relevance of breast cancer cell lines as models for breast tumours: an update".  
  4. ^ Lacroix, M; Haibe-Kains B; Hennuy B; Laes JF; Lallemand F; Gonze I; Cardoso F; Piccart M; Leclercq G; Sotiriou C. (2004). "Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes". Oncology Reports 12 (4): 701–707.  
  5. ^ Lacroix, M; Leclercq G, on behalf of BreastMed Consortium (2005). "The "portrait" of hereditary breast cancer".  
  6. ^ De Longueville, F; Lacroix M (co-first author), Barbuto AM, Bertholet V, Gallo D, Larsimont D, Marcq L, Zammatteo N, Boffe S, Leclercq G, Remacle J. (2005). "Molecular characterization of breast cancer cell lines by a low-density microarray".  
  7. ^ Lacroix, M; Toillon RA; Leclercq G. (2006). "P53 and breast cancer, an update". Endocrine-Related Cancer 13 (2): 293–325.  
  8. ^ Lacroix., M (2006). "Significance, detection and markers of disseminated breast cancer cells". Endocrine-Related Cancer 13 (4): 1033–1067.  
  9. ^ Lacroix., M (2008). "Persistent use of "false" cell lines". International Journal of Cancer 122 (1): 1–4.  
  10. ^ Lacroix, M; Siwek B; Marie PJ; Body JJ. (1998). "Production and regulation of  
  11. ^ Sotiriou, C; Lacroix M (co-first author), Lagneaux L, Berchem G, Body JJ. (1999). "The  
  12. ^ Sotiriou, C; Lacroix M; Lespagnard L; Larsimont D; Paesmans M; Body JJ. (2001). "Interleukins-6 and-11 expression in primary breast cancer and subsequent development of bone metastases". Cancer Letters 169 (1): 87–95.  
  13. ^ Lacroix, M; Siwek B; Body JJ. (1996). "Effects of secretory products of breast cancer cells on  
  14. ^ Siwek, B; Lacroix M; DePollak C; Marie P; Body JJ. (1997). "Secretory products of breast cancer cells specifically affect human osteoblastic cells: Partial characterization of active factors". Journal of Bone and Mineral Research 12 (4): 552–560.  
  15. ^ Lacroix, M; Lacroix M; Marie PJ; Body JJ. (2000). "Protein production by osteoblasts: modulation by breast cancer cell-derived factors".  
  16. ^ Lacroix, M; Body JJ. (1997). "Regulation of  
  17. ^ Lacroix, M; Siwek B; Body JJ. (1998). "Breast cancer cell response to  
  18. ^ Jin, L; Borras M; Lacroix M; Legros N; Leclercq G. (1995). "Antiestrogenic activity of 2 11-beta-estradiol derivatives on MCF-7 breast cancer cells".  
  19. ^ Borras, M; Lacroix M; Legros N; Leclercq G. (1997). " 
  20. ^ Maaroufi, Y; Lacroix M; Lespagnard L; Journe F; Larsimont D; Leclercq G. (2000). "Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis". Breast Cancer Research 2 (6): 444–454.  
  21. ^ Lacroix, M; Querton G; Hennebert P; Larsimont D; Leclercq G. (2001). "Estrogen receptor analysis in primary breast tumors by ligand-binding assay, immmocytochemical assay, and northern blot: a comparison".  
  22. ^ Rivas, A; Lacroix M; Olea-Serrano F; Laios I; Leclercq G; Olea N. (2002). "Estrogenic effect of a series of bisphenol analogues on gene and protein expression in MCF-7 breast cancer cells". Journal of Steroid Biochemistry and Molecular Biology 82 (1): 45–53.  
  23. ^ Lacroix, M; Leclercq G. (2004). "About GATA3, HNF3A, and XBP1, three genes co-expressed with the oestrogen receptor-alpha gene (ESR1) in breast cancer". Molecular and Cellular Endocrinology 219 (1–2): 1–7.  
  24. ^ Toillon, RA; Magné N, Laios I, Lacroix M, Duvillier H, Lagneaux L, Devriendt D, Van Houtte P, Leclercq G. (2005). "Interaction between estrogen receptor alpha, ionizing radiation and (anti-) estrogens in breast cancer cells".  
  25. ^ Leclercq, G; Lacroix M; Laïos I; Laurent G. (2006). "Estrogen receptor alpha: impact of ligands on intracellular shuttling and turnover rate in breast cancer cells". Current Cancer Drug Targets 6 (1): 39–64.  
  26. ^ Toillon, RA; Magné N, Laïos I, Castadot P, Kinnaert E, Van Houtte P, Desmedt C, Leclercq G, Lacroix M. (2007). "Estrogens decrease gamma-rays induced senescence and maintain cell cycle progression in breast cancer cells independently of p53". International Journal of Radiation Oncology, Biology, Physics 67 (4): 1187–1200.  
  27. ^ Lacroix, M; Toillon RA; Leclercq G. (2004). "Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics". Endocrine-Related Cancer 11 (3): 497–522.  

Bibliography: collaborative books - invited chapters

  • Leclercq G, Lacroix M, Seo HS, Larsimont D. "Mechanisms regulating oestrogen receptor alpha expression in breast cancer.", in "Molecular Mechanisms of Action of Steroid Hormone Receptors" 65–75 (2002). Editors: Marija Krstic-Demonacos & Constantinos Demonacos, Research Signpost Publishers, Trivandrum, India, ISBN 81-7736-129-5, http://www.ressign.com/
  • Lacroix, Marc; Guy Leclercq (2004). "An Updated View on Cell Lines as in Vitro Models for Breast Tumors". In Andrew P. Yao (ed.). Focus on Breast Cancer Research. Commack, N.Y: Nova Science Publishers. pp. 131–182.  
  • Sotiriou C, Desmedt C, Durbecq V, Dal Lago L, Lacroix M, Cardoso F, Piccart M. "Genomic and molecular classification of breast cancer.", in "Molecular Oncology of Breast Cancer" 81–95 (2004). Editors: Jeffrey S. Ross and Gabriel N. Hortobagy, Jones and Bartlett Publishers, 40 Tall Pine Drive, Sudbury, MA 01776 USA, ISBN 0-7637-4810-2, http://www.jbpub.com/catalog/0763748102/table_of_contents.htm
  • Lacroix, Marc; Guy Leclercq (2006). "Hereditary Breast Cancer: An Update on Genotype and Phenotype". In Andrew P. Yao (ed.). New Breast Cancer Research (Horizons in Cancer Research). Commack, N.Y: Nova Science Publishers. pp. 27–51.  
  • Lacroix, Marc (2007). "An Update on Tumor Suppressor Genes in Breast Cancer". In Katherine R. Polinsky (ed.). Tumor Suppressor Genes. Commack, N.Y: Nova Science Publishers. pp. 177–256.  
  • Lacroix, Marc (2008). "Disseminated Tumor Cells: Detection, Markers and Prognostic/Predictive Significance". In Akira Watanabe (ed.). Cancer Metastases Research Progress. Commack, N.Y: Nova Science Publishers. pp. 1–45.  
  • Lacroix, Marc (2010). "MicroRNAs in Breast Cancer". In Martin E. Romero and Louis M. Dashek (ed.). Breast Cancer: Causes, Diagnosis and Treatment. Commack, N.Y: Nova Science Publishers. pp. 1–53.  
  • Lacroix, Marc (2011). "MicroRNAs in Breast Cancer". In Eileen C. Roswell (ed.). Encyclopedia of Breast Cancer Research. Commack, N.Y: Nova Science Publishers. pp. ?.  
  • Lacroix, Marc (2012). "MicroRNAs in Breast Cancer". In Gao Shi Tsai and Kong Ai Toh (ed.). Cancer Researcher Biographical Sketches and Research Summaries. Commack, N.Y: Nova Science Publishers. p. 171.  

Bibliography: books

  • Lacroix M. Tumor suppressor genes in breast cancer (2008). Nova Science Publishers, Inc, 400 Oser Ave, Ste 1600, Hauppauge, NY 11788-3635 USA, https://www.novapublishers.com/catalog/product_info.php?products_id=6866 ISBN 978-1-60456-326-9
  • Lacroix M. Molecular therapy of breast cancer: classicism meets modernity (2009). Nova Science Publishers, Inc, 400 Oser Ave, Ste 1600, Hauppauge, NY 11788-3635 USA, https://www.novapublishers.com/catalog/product_info.php?products_id=10042 ISBN 978-1-60741-593-0
  • Lacroix M. MicroRNAs in breast cancer (2010). Nova Science Publishers, Inc, 400 Oser Ave, Ste 1600, Hauppauge, NY 11788-3635 USA, https://www.novapublishers.com/catalog/product_info.php?products_id=12776 ISBN 978-1-61668-438-9
  • Lacroix M. A concise history of breast cancer (2011, 2013). Nova Science Publishers, Inc, 400 Oser Ave, Ste 1600, Hauppauge, NY 11788-3635 USA, https://www.novapublishers.com/catalog/product_info.php?cPath=23_132_105&products_id=18309 ISBN 978-1-61122-305-7 (2011), https://www.novapublishers.com/catalog/product_info.php?products_id=40565&osCsid=eab93c77d43f686ab6e8108d41306b3c (2013)
  • Lacroix M. Coding for disease: genes and cancer (2013). Nova Science Publishers, Inc, 400 Oser Ave, Ste 1600, Hauppauge, NY 11788-3635 USA, https://www.novapublishers.com/catalog/product_info.php?products_id=41346 ISBN 978-1-62257-817-7
  • Lacroix M. Targeted therapies in cancer (2014). Nova Science Publishers, Inc, 400 Oser Ave, Ste 1600, Hauppauge, NY 11788-3635 USA, https://www.novapublishers.com/catalog/product_info.php?products_id=50896 ISBN 978-1-63321-676-1

References

Over the years, Marc Lacroix has been refereeing for several international scientific and clinical journals:

External links

  • Free access to "Relevance of breast cancer cell lines as models for breast tumours: an update"
  • Free access to "Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes"
  • Free access to "Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis"
  • Free access to "Stable 'portrait' of breast tumors during progression: data from biology, pathology and genetics"
  • Free access to "P53 and breast cancer, an update"
  • Free access to "Persistent use of ‘‘false’’ cell lines"
  • Free access to "Significance, detection and markers of disseminated breast cancer cells"
  • Free access to "Disseminated tumor cells: detection, markers and prognostic/predictive significance"
  • Free access to "Hereditary breast cancer: an update on genotype and phenotype"
  • Free access to "Establishment and characterization of three new breast-cancer cell lines"
  • Free access to "Estrogen Receptor Alpha: Impact of Ligands on Intracellular Shuttling and Turnover Rate in Breast Cancer Cells"
  • Université libre de Bruxelles – Marc Lacroix
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from Hawaii eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.